Avacta Group PLC (AVCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avacta Group PLC (AVCT) has a cash flow conversion efficiency ratio of -93.806x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-13.51 Million ≈ $-1.64K USD) by net assets (GBX144.00K ≈ $17.52 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AVCT cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Avacta Group PLC - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Avacta Group PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Avacta Group PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avacta Group PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GLOW LIFETECH CORP.
F:9DO
|
0.054x |
|
Advance Information Marketing Bhd
KLSE:0122
|
0.010x |
|
SPOBAG AG
F:SBE
|
N/A |
|
AGS Transact Technologies Limited
NSE:AGSTRA
|
0.198x |
|
ARC Funds Ltd
AU:ARC
|
-0.304x |
|
Octopus Titan VCT
LSE:OTV2
|
-0.015x |
|
New Concept Energy Inc
NYSE MKT:GBR
|
-0.015x |
|
The House of Agriculture Spiroy S.A.
AT:SPIR
|
0.757x |
Annual Cash Flow Conversion Efficiency for Avacta Group PLC (2001–2024)
The table below shows the annual cash flow conversion efficiency of Avacta Group PLC from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see AVCT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX9.28 Million ≈ $1.13K |
GBX-23.60 Million ≈ $-2.87K |
-2.543x | -272.78% |
| 2023-12-31 | GBX21.80 Million ≈ $2.65K |
GBX-14.87 Million ≈ $-1.81K |
-0.682x | +23.47% |
| 2022-12-31 | GBX18.44 Million ≈ $2.24K |
GBX-16.43 Million ≈ $-2.00K |
-0.891x | -79.15% |
| 2021-12-31 | GBX41.22 Million ≈ $5.02K |
GBX-20.51 Million ≈ $-2.49K |
-0.497x | -189.48% |
| 2020-12-31 | GBX61.93 Million ≈ $7.53K |
GBX-10.64 Million ≈ $-1.29K |
-0.172x | +32.71% |
| 2018-07-31 | GBX21.41 Million ≈ $2.61K |
GBX-5.47 Million ≈ $-665.30 |
-0.255x | -79.97% |
| 2017-07-31 | GBX29.89 Million ≈ $3.64K |
GBX-4.24 Million ≈ $-516.01 |
-0.142x | -20.19% |
| 2016-07-31 | GBX35.86 Million ≈ $4.36K |
GBX-4.23 Million ≈ $-515.03 |
-0.118x | +10.19% |
| 2015-07-31 | GBX19.13 Million ≈ $2.33K |
GBX-2.52 Million ≈ $-306.00 |
-0.131x | -352.36% |
| 2014-07-31 | GBX28.84 Million ≈ $3.51K |
GBX-838.00K ≈ $-101.96 |
-0.029x | +67.18% |
| 2013-07-31 | GBX15.55 Million ≈ $1.89K |
GBX-1.38 Million ≈ $-167.54 |
-0.089x | -111.16% |
| 2012-07-31 | GBX16.96 Million ≈ $2.06K |
GBX-711.00K ≈ $-86.51 |
-0.042x | +19.54% |
| 2011-07-31 | GBX11.44 Million ≈ $1.39K |
GBX-596.00K ≈ $-72.52 |
-0.052x | +70.16% |
| 2010-07-31 | GBX9.97 Million ≈ $1.21K |
GBX-1.74 Million ≈ $-211.83 |
-0.175x | +48.24% |
| 2009-07-31 | GBX8.30 Million ≈ $1.01K |
GBX-2.80 Million ≈ $-340.56 |
-0.337x | -26.84% |
| 2008-07-31 | GBX4.87 Million ≈ $592.42 |
GBX-1.29 Million ≈ $-157.56 |
-0.266x | +44.06% |
| 2007-07-31 | GBX2.63 Million ≈ $319.87 |
GBX-1.25 Million ≈ $-152.09 |
-0.475x | +95.21% |
| 2006-04-30 | GBX14.00K ≈ $1.70 |
GBX-139.00K ≈ $-16.91 |
-9.929x | -148.21% |
| 2005-04-30 | GBX21.00K ≈ $2.56 |
GBX-84.00K ≈ $-10.22 |
-4.000x | -916.22% |
| 2004-04-30 | GBX1.03 Million ≈ $125.81 |
GBX-407.00K ≈ $-49.52 |
-0.394x | -315.55% |
| 2003-04-30 | GBX-230.00K ≈ $-27.98 |
GBX-42.00K ≈ $-5.11 |
0.183x | -8.87% |
| 2002-04-30 | GBX-529.00K ≈ $-64.36 |
GBX-106.00K ≈ $-12.90 |
0.200x | -47.29% |
| 2001-04-30 | GBX-363.00K ≈ $-44.17 |
GBX-138.00K ≈ $-16.79 |
0.380x | -- |
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more